Larry Edwards has been appointed chief operating officer, Tetraphase Pharmaceuticals. Mr. Edwards, previously chief commercial officer, will also continue to oversee all aspects of pre-commercialization activities for eravacycline in complicated intra-abdominal infections (cIAI).

Mr. Edwards joined Tetraphase in 2015 as vice president of marketing, became vice president of commercial operations in 2016, and was appointed chief commercial officer in early 2017. Prior to joining Tetraphase, Mr. Edwards served as senior director of marketing, Gram Negative Franchise, with Cubist Pharmaceuticals, Inc. (later acquired by Merck), where he was responsible for all pre-launch or post-launch marketing activities for ZERBAXA. Prior to Cubist, he was global marketing director, Clostridium Difficile & New Infectious Disease Products, with Merck & Co.

“Larry is a natural leader and the best candidate for the role of Tetraphase’s chief operating officer, with his expertise in commercializing and marketing antibiotics and a solid track record of leadership within the company,” said Guy Macdonald, president and chief executive officer of Tetraphase. “As we continue to prepare for the potential commercialization of our lead candidate, eravacycline in cIAI, Larry’s guidance in both the pre-commercial activities, as well as overseeing operations, will be essential in ensuring that we are poised for a strong commercial launch in the U.S. and Europe in the second half of the year, assuming regulatory approvals.”